Abstract
Objective
High dose intravenous stilboestrol has a direct cytotoxic effect on prostatic carcinoma cells. The purpose of this study was to assess subjective and objective responses in a select group of patients with metastatic, hormonerefractory carcinoma of the prostate with severe generalized bone pain in association with symptoms of advanced local disease.
Patients and methods
Seventeen patients with metastatic carcinoma of the prostate, who had relapsed following a good initial response to androgen ablation, were treated as inpatients with once daily intravenous injection of 1104 mg diethylstilboestrol diphosphate (Honvan™, Asta Medica, Cambridge, UK) for 7 days. The hormone-refractory status was confirmed by castrate serum testosterone levels. All the patients had failed to respond to second-line hormone manipulation and had progressive disease.
All the patients had generalized bone pain, 11 also had symptoms of bladder outlet obstruction, 3 had recurrent haematuria and 3 had both. The mean age was 74 years (range 59–83), mean time to chemical relapse (rising PSA) was 29 months (range 1–70), and mean time to clinical relapse was 37 months (range 6–98).
The WHO pain score, performance status score, and a patient-specific quality of life (daily living activity) were used as the subjective measures and the serum PSA as an objective marker. All the parameters were recorded before, during and up to three months after treatment.
Results
Two patients had a transient relief of bone pain with the pain score reducing by two points. Overall, the pain and performance scores and the local symptoms did not improve. The PSA level continued to rise in all patients.
Despite parenteral pre-medication with pethidine and cyclizine, all the patients suffered nausea and pain following the injection. One patient died on the fifth day of treatment from a myocardial infarction and 4 developed deep vein thrombosis. All the patients required further symptom control measures.
Conclusion
High dose intravenous stilboestrol causes considerable morbidity without any objective or subjective response in the treatment of patients with symptomatic, hormone-refractory metastatic carcinoma of the prostate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Isaac, J. T., Schulz, I. I., Coffey, D. S.: Development of androgen resistance in prostatic cancer. In: Murphy, G., Khoury, S., Kuss, R., Chatelain, C., Denis, L. (eds.): Prostate Cancer, Part A. Research: Endocrine Treatment and Histopathology. Alan R. Liss, New York 1987, pp. 21–31.
Fossa, S. D., Aaronson, N. K., Newling, D.: Quality of life in and treatment of hormone resistant metastatic prostatic cancer.Eur. J. Cancer, 26, 1133 (1990).
George, N. J. R.: Natural history of localized prostatic carcinoma managed by conservative therapy alone.Lancet, 1, 494 (1988).
Dearnaley, D. P., Bayly, R. J., A'Hern, R. P., Gadd, J., Zivanovic, M. M., Lewington, V. J.: Palliation of bone metastasis in prostate cancer, hemibody irradiation or strontium-89.Clin. Oncol., 4, 101 (1992).
Klijn, J. G. M.: Scientific background of hormonal treatment of prostatic cancer. In: EORTC Genitourinary Group Monograph 7. Prostate Cancer and Testicular Cancer. Wiley-Liss, New York 1990, pp. 7–22.
Thompson, T. C.: Growth factors and oncogenes in prostate cancer.Cancer Cells, 2, 345 (1990).
Ferro, M. A., Heinemann, D., Smith, P. J. B., Symes, M. O.: The effect of stilboestrol and testosterone on the incorporation of 75-selenomethionine by prostatic carcinoma cells.Br. J. Urol., 62 (2), 166 (1988).
Schulz, P., Vetter, I., Fittler, F.: Evaluation of cytotoxic activity of stilboestrol and its phosphorylated derivative towards prostatic carcinoma, non-prostatic neoplastic and non-transformed cells.Urol. Int., 43, (Suppl. 1), 5 (1988).
Schneider, M. R., Schonenberger, H.: Effects of diethylstilboestrol and its mono-and diphosphate on experimental mammary and prostatic tumors.Urol. Int., 43, (Suppl. 1), 5 (1988).
Ferro, M. A., Gillatt, D., Symes, M. D., Smith, P. J. B.: High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response.Urology, 34 (3), 134 (1989).
Mahler, C., Keuppens, F., Nowe, P.,Van Erps, P., Denis, L.: Prospective study of diethylstilboestrol-diphosphate in the treatment of prostate cancer in relapse.Urol. Int., 43 (Suppl. 1), 47 (1988).
Brandes, D., Bourne, G. H.: Stilboestrol phosphate and prostatic carcinoma.Lancet, 1, 481 (1955).
Droz, J. P., Kattan, J., Bannau, M., Chraibu, Y., Bekradda, M.: High-dose continuous-infusion Fosfestrol in hormone-resistant prostate cancer.Cancer, 71, (Suppl. 3), 1123 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ahmed, M., Choksy, S., Chilton, C.P. et al. High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate. International Urology and Nephrology 30, 159–164 (1998). https://doi.org/10.1007/BF02550571
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02550571